Lundbeck's Bocunebart Meets Primary Endpoint in Phase IIb Migraine Prevention Trial
Key Insights
Lundbeck's bocunebart (search) (Lu AG09222) achieved its primary endpoint in the phase IIb PROCEED trial, demonstrating statistically significant reduction in monthly migraine (search) days compared to placebo over 12 weeks.
The investigational anti-PACAP (search) monoclonal antibody showed efficacy in 431 patients who had experienced 1-4 previous preventive treatment failures, representing a difficult-to-treat population.
Bocunebart (search) targets a novel pathway distinct from anti-CGRP therapies, potentially offering the first PACAP (search)-targeting option for migraine (search) prevention.
H. Lundbeck A/S announced positive results from the intravenous dosing portion of its phase IIb PROCEED trial, with bocunebart (search) (Lu AG09222) meeting its primary endpoint for migraine (search) prevention. The investigational anti-PACAP (search) monoclonal antibody demonstrated a statistically significant difference compared to placebo in reducing monthly migraine days over weeks 1 to 12 in patients who had experienced previous treatment failures.
Trial Design and Patient Population
The PROCEED trial was an adaptive phase IIb dose-finding and route of administration study that enrolled 431 patients across 14 countries, including Bulgaria, Czechia, Denmark, France, Georgia, Germany, Hungary, Lithuania, Japan, Poland, Romania, Slovakia, Spain, and the United States. The trial assessed bocunebart (search) administered once monthly for three months, comparing efficacy, safety, and tolerability versus placebo.
The study specifically targeted patients diagnosed with migraine (search) according to the International Classification of Headache Disorders Third Edition (ICHD-3) who had experienced treatment failure with 1-4 different preventive migraine medications in the past 10 years. This represents a particularly challenging patient population with significant unmet medical needs.
The primary efficacy endpoint was defined as the difference between bocunebart (search) and placebo in the mean change from baseline in the number of monthly migraine (search) days over weeks 1 to 12.
Novel Mechanism of Action
Bocunebart (search) is engineered to bind to and inhibit the signaling of pituitary adenylate cyclase-activating polypeptide (search) (PACAP (search)), a neuropeptide implicated in migraine (search) pathophysiology. This mechanism operates through a pathway distinct from that targeted by anti-calcitonin gene-related peptide (anti-CGRP) therapies, potentially representing a new treatment class for migraine prevention.
"These data underline Lundbeck's ambition to deliver the first PACAP (search) targeting option in migraine (search) prevention. With its novel mechanism of action, it has the potential to become an important addition to the migraine treatment paradigm," said Dr. Johan Luthman, EVP and Head of Research & Development at Lundbeck.
Safety Profile and Previous Results
Bocunebart (search) was generally well tolerated during the PROCEED trial, with no new safety signals detected. These results build on findings from the previously successful HOPE phase IIa trial, which evaluated single intravenous administration of bocunebart.
Dr. Jessica Ailani, certified headache specialist in Washington DC and coordinating investigator of the trial, commented: "I am encouraged by the positive results from the PROCEED trial. The efficacy demonstrated in this trial represent a promising advancement in the treatment of migraine (search), offering hope to many patients suffering from this debilitating condition."
Next Steps and Regulatory Path
Based on the positive outcome, Lundbeck plans to approach regulatory authorities to discuss the results and phase III design options. Additional analyses will be conducted to better understand the dose-response relationship across the investigated doses.
The trial results are planned to be presented at an upcoming conference and submitted for scientific publication. Bocunebart (search) remains an investigational compound, not approved by the US Food and Drug Administration or any other regulatory agency.
Disease Burden Context
Migraine (search) is characterized as a complex and incapacitating neurological disease featuring recurrent episodes of moderate to severe, pulsating headaches typically accompanied by nausea, vomiting, and sensitivity to light and sound. As the most prevalent neurological disorder in people aged under 50 years, migraine affects around 135 million people in the G7 countries plus China, imposing both social and financial burdens on patients and healthcare systems.